Results 61 to 70 of about 6,571 (189)
pharma-kritik, 2008 Mit Vildagliptin steht - neben Sitagliptin - ein weiterer sogen. DPP-4-Hemmer zur Verfügung. Das Medikament senkt das HbA1c weniger stark als Metformin. Daten zu klinisch relevanten Endpunkten liegen noch keine vor.
openaire +1 more source
The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli +3 more
wiley +1 more source
Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Advanced Materials, Volume 38, Issue 51, 11 September 2026.Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa +3 more
wiley +1 more source
Valsartan and Amlodipine Improved Haematological and Biochemical Indices of Vildagliptin-treated Streptozotocin-induced Diabetic Rats [PDF]
Pharmaceutical and Biomedical ResearchBackground: Diabetes mellitus (DM) and hypertension often coexist in sufferers, which exacerbates the complications of DM. Also, the impacts of antihypertensive medications on the treatment outcomes of DM are not fully understood.
Israel Olapeju Bolanl +7 more
doaj
Mitigating effects of vildagliptin in experimental diabetes with metabolic syndrome [PDF]
, 2016 Background: Vildagliptin has multiple beneficial effects reported in isolated studies like anti-diabetic, cardio protective, anti-inflammatory and antioxidant.
Borde, Manjusha K. +4 more
core +1 more source
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.The comparative pharmacology and cardiometabolic outcomes of semaglutide, liraglutide and tirzepatide, integrating evidence from major clinical trial programs and meta‐analyses. ABSTRACT Background Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges.
Hiba Bawadi +4 more
wiley +1 more source
Vildagliptin-induced hepatotoxicity: A case report
, 2016 Vildagliptin-induced hepatotoxicity: A casereportAuthors: Seydahmet Akin1, Şakir Özgür Keşkek2, Sinan Kazan1, Asli Ocal1, Meh-met Aliustaoglu11Dr. Lutfi Kirdar Kartal Training and Research Hospital, Department of Internal Medi-cine, Istanbul, Turkey ...
Kazan, Sinan +4 more
core +1 more source
Ferroptosis: Newly Emerged Regulator for Human Disease
MedComm, Volume 7, Issue 9, September 2026.Ferroptosis is a key regulated cell death pathway closely involved in cancers, neurodegenerative disorders, acute organ injuries, and cardiovascular and chronic metabolic diseases, representing a promising therapeutic target for diverse human illnesses.
Dandan Xiao +4 more
wiley +1 more source
Bullous pemphigoid induced by vildagliptin: a report of three cases
, 2015 International audienceTo report three cases of bullous pemphigoid in patients treated with vildagliptin. Case 1: An 86-year-old woman presented with bullous pemphigoid after 1 month of treatment with vildagliptin and metformin.
Anne‐Fleur Tronquoy +21 more
core +1 more source
Therapeutic Advances in Endocrinology and Metabolism, 2015 Objective: The present study aimed to assess the patient preference and tolerability of oral dipeptidyl peptidase-4 inhibitor (vildagliptin) versus injectable glucagon-like peptide-1 analog (liraglutide) in patients with type 2 diabetes mellitus ...
Jörg Lüdemann +2 more
doaj +1 more source